Alzheimer's disease - Time to act is now

Ceylon Medical Journal

Volumn 50, Issue 1, 2005, Pages 1-4

  De Silva, H A ^a  

^a UNIVERSITY OF KELANIYA   (Sri Lanka)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; DAILY LIFE ACTIVITY; ENZYMOLOGY; HUMAN; MENTAL CAPACITY; METABOLISM; PROGRAM DEVELOPMENT;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; HUMANS; MENTAL COMPETENCY; PROGRAM DEVELOPMENT;

EID: 20644451193     PISSN: 00090875     EISSN: None     Source Type: Journal    
DOI: 10.4038/cmj.v50i1.1580     Document Type: Editorial

References (19)

1. Terry R, Katzman R, Bick KL, Sissodia SS, eds. Alzheimer's Disease. 2nd ed. Philadelphia: 1999.
2. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association: Washington DC, 1994.
3. Feldman H, Sauter A, Donald A, et al. The Disability Assessment of Dementia Scale. A 12-month study of functional ability in mild to moderate severity Alzheimer's disease. Alzheimer's Disease and Associated Disorders 2001; 15: 89-95.
4. Schulz R, O'Brien AT, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes. Gerontologist 1995; 35: 771-91.
5. Hendrie HC. Epidemiology of dementia and Alzheimer's disease. American Journal of Geriatric Psychiatry 1998; 6 (2 Suppl 1): S3-S18.
6. Clark CM, Karlawish JT. Alzheimer's disease: current concepts and emerging diagnostic and therapeutic strategies. Annals of Internal Medicine 2003; 138: 400-10.
7. Chandra V, Ganguli M, Pandav R, Johnston J, Belle S, et al. Prevalence of Alzheimer's disease and other dementias in rural India: The Indo-US study. Neurology 1998; 51: 1000-8.
8. Rajkumar S, Kumar S. Prevalence of dementia in the community: a rural-urban comparison from Madras, India. Australian Journal of Ageing 1996; 15: 9-13.
9. De Silva HA, Gunatilake SB, Smith AD. Prevalence of dementia in a semi-urban community in Sri Lanka: report from a regional survey. International Journal of Geriatric Psychiatry 2003; 18: 711-5.
10. National Institute for Clinical Excellence. Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. London: NICE, 2001.
11. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154-6.
12. De Silva HA, Gunatilake SB. Rivastigmine in the treatment of Alzheimer's disease. Sri Lanka Prescriber 2002; 10: 5-6.
13. Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. Journal of the American Geriatric Society 2003; 51: 737-44.
14. Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2004; 17: 100-8.
15. Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Canadian Medical Association Journal 2003; 169: 557-64.
16. Pearce KA, Furberg CD, Psaty BM, Kirk J. Cost-minimisation and the number needed to treat in uncomplicated hypertension. American Journal of Hypertension 1998; 11: 618-29.
17. Farlow MR, Hake A, Messina J, Hartman R, Veech J, et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology 2001; 58: 417-22.
18. De Silva HA, Gunatilake SB, Johnston C, Warden D, Smith AD. Medial temporal lobe atrophy, apolipoprotein genotype and plasma homocysteine in Sri Lankan patients with Alzheimer's disease. Experimental Aging Research 2005 (In press)
19. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol and misfolded proteins. Lancet 2004; 363: 1139-46.